^
    Back
    Association details:
    Biomarker:NRG1 fusion
    Cancer:Pancreatic Cancer
    Drug:Gilotrif (afatinib) (EGFR inhibitor, HER2 inhibitor, HER4 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    Clin Cancer Res
    Title:

    NRG1 Gene Fusions Are Recurrent, Clinically Actionable Gene Rearrangements in KRAS Wild-Type Pancreatic Ductal Adenocarcinoma

    Excerpt:
    Two of 3 patients with NRG1 fusion-positive tumors were treated with afatinib and demonstrated a significant and rapid response while on therapy.
    DOI:
    10.1158/1078-0432.CCR-19-0191
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    AACR 2021
    Title:

    Preclinical activity of seribantumab in gastrointestinal cancers with NRG1 fusions

    Published date:
    03/10/2021
    Excerpt:
    Expression of NRG1 fusions in H6c7 cells resulted in enhanced phosphorylation of HER3 and AKT and increased sensitivity to afatinib, as compared to empty vector control cells